Titre
Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial.
Type
article
Institution
Externe
Périodique
Auteur(s)
Hartmann, A.
Auteure/Auteur
Müllner, J.
Auteure/Auteur
Meier, N.
Auteure/Auteur
Hesekamp, H.
Auteure/Auteur
van Meerbeeck, P.
Auteure/Auteur
Habert, M.O.
Auteure/Auteur
Kas, A.
Auteure/Auteur
Tanguy, M.L.
Auteure/Auteur
Mazmanian, M.
Auteure/Auteur
Oya, H.
Auteure/Auteur
Abuaf, N.
Auteure/Auteur
Gaouar, H.
Auteure/Auteur
Salhi, S.
Auteure/Auteur
Charbonnier-Beaupel, F.
Auteure/Auteur
Fievet, M.H.
Auteure/Auteur
Galanaud, D.
Auteure/Auteur
Arguillere, S.
Auteure/Auteur
Roze, E.
Auteure/Auteur
Degos, B.
Auteure/Auteur
Grabli, D.
Auteure/Auteur
Lacomblez, L.
Auteure/Auteur
Hubsch, C.
Auteure/Auteur
Vidailhet, M.
Auteure/Auteur
Bonnet, A.M.
Auteure/Auteur
Corvol, J.C.
Auteure/Auteur
Schüpbach, M.
Auteure/Auteur
Liens vers les personnes
ISSN
1932-6203
Statut éditorial
Publié
Date de publication
2016
Volume
11
Numéro
7
Première page
e0158235
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Randomized Controlled Trial
Publication Status: epublish
Publication Status: epublish
Résumé
In the present study, we examined the potential symptomatic and/or disease-modifying effects of monthly bee venom injections compared to placebo in moderatly affected Parkinson disease patients. We conducted a prospective, randomized double-blind study in 40 Parkinson disease patients at Hoehn & Yahr stages 1.5 to 3 who were either assigned to monthly bee venom injections or equivalent volumes of saline (treatment/placebo group: n = 20/20). The primary objective of this study was to assess a potential symptomatic effect of s.c. bee venom injections (100 μg) compared to placebo 11 months after initiation of therapy on United Parkinson’s Disease Rating Scale (UPDRS) III scores in the « off » condition pre-and post-injection at a 60 minute interval. Secondary objectives included the evolution of UPDRS III scores over the study period and [123I]-FP-CIT scans to evaluate disease progression. Finally, safety was assessed by monitoring specific IgE against bee venom and skin tests when necessary. After an 11 month period of monthly administration, bee venom did not significantly decrease UPDRS III scores in the « off » condition. Also, UPDRS III scores over the study course, and nuclear imaging, did not differ significantly between treatment groups. Four patients were excluded during the trial due to positive skin tests but no systemic allergic reaction was recorded. After an initial increase, specific IgE against bee venom decreased in all patients completing the trial. This study did not evidence any clear symptomatic or disease-modifying effects of monthly bee venom injections over an 11 month period compared to placebo using a standard bee venom allergy desensitization protocol in Parkinson disease patients. However, bee venom administration appeared safe in non-allergic subjects. Thus, we suggest that higher administration frequency and possibly higher individual doses of bee venom may reveal its potency in treating Parkinson disease.
ClinicalTrials.gov NCT01341431.
ClinicalTrials.gov NCT01341431.
PID Serval
serval:BIB_B1B2BB2235AA
PMID
Open Access
Oui
Date de création
2025-04-17T09:21:31.462Z
Date de création dans IRIS
2025-05-21T02:17:20Z